Biotech capital markets remain resilient, with significant M&A activity offsetting policy uncertainty and a shifting IPO landscape. Big Pharma’s patent cliff continues to drive aggressive deal-making, even as acquisition premiums compress. Clinical developments dominate the sector, highlighted by Moderna’s positive melanoma vaccine data and Revolution Medicines’ rapid FDA approval for pancreatic cancer, contrasted by the failure of AstraZeneca and Ionis’s ATTR cardiomyopathy combination therapy. Regulatory focus centers on the nomination of Dr. Heidi Overton as FDA commissioner and increasing scrutiny regarding the validity of clinical data sourced from China. Meanwhile, the industry faces mounting pressure over the premium pricing of new therapies, which complicates market access and risks public perception. These developments underscore a broader tension between the necessity of high-cost innovation and the financial sustainability of global healthcare systems.
Sign in to continue reading, translating and more.
Open full episode in Podwise